Compugen Ltd. CGEN
Set alert
At close · Oct 30
After hours · Oct 30, 4:31 PM ET
- YTD
- +29.41%
- 1 year
- +20.00%
- Open
- 2.02
- Prev close
- 2.04
- Mkt cap
- 187.55M
- Vol
- 255.46K
- Avg vol
- 253.92K
- EPS
- 0.38
- P/E
- 5.21
- Div yield
- 0.00%
More statistics
- Low
- 1.92
- High
- 2.02
- Forward P/E
- -13.82
- Beta
- 2.65
- Short ratio
- 6.42
- Inst. own
- 14.97%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.61
- 200-d avg
- 1.91
- 1y target
- 4.00
News
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
3 weeks ago defenseworld.net
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen (NASDAQ: CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into…
3 weeks ago prnewswire.com
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI,…
3 weeks ago marketbeat.com
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into…
3 weeks ago seekingalpha.com
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
1 month ago defenseworld.net
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison
Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
1 month ago prnewswire.com
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.
1 month ago prnewswire.com
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
2 months ago zacks.com
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago zacks.com
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
2 months ago seekingalpha.com
Compugen: Better Runway Ahead Of MAIA
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway…
3 months ago seekingalpha.com
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
3 months ago marketbeat.com
Compugen Q2 Earnings Call Highlights
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash…
3 months ago zacks.com
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
-
3 months ago benzinga.com
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period…
3 months ago prnewswire.com
Compugen Reports Second Quarter 2026 Results
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the…
3 months ago prnewswire.com
Compugen to Participate in BTIG Biotechnology Conference 2026
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML,…
3 months ago prnewswire.com
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by…
-
4 months ago benzinga.com
Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Adaptive Platform Trial Of COM701, Potential Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress…
4 months ago prnewswire.com
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by…
4 months ago seekingalpha.com
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
-
4 months ago benzinga.com
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will…
4 months ago prnewswire.com
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery…
4 months ago prnewswire.com
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML,…
5 months ago benzinga.com
Compugen Q1 2026 Earnings Call: Complete Transcript
Compugen Q1 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year. The…
-
6 months ago benzinga.com
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6
Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $6.
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
8 months ago benzinga.com
Compugen Q4 EPS $0.60 Beats $0.05 Estimate, Sales $67.332M Beat $1.357M Estimate
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.05 by 1100 percent. This is a 957.14 percent increase over losses of $(0.07) per…
-
8 months ago benzinga.com
Uncovering Potential: Compugen's Earnings Preview
Uncovering Potential: Compugen's Earnings Preview
9 months ago benzinga.com
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
-
9 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $4.
-
10 months ago benzinga.com
Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered…
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
11 months ago benzinga.com
Compugen Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $1.891M Beat $1.469M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 800 percent decrease over earnings of $0.01 per…
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
1 year ago benzinga.com
Compugen Publishes Pooled Data Showing COM701 Activity in Platinum-Resistant Ovarian Cancer Ahead of ESMO Presentation
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that pooled…
-
1 year ago benzinga.com
Compugen Q2 EPS $(0.08) Misses $(0.07) Estimate, Sales $1.257M Miss $3.952M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 23.08 percent. This is a 300 percent decrease over losses of $(0.02)…
-
1 year ago benzinga.com
Compugen Q1 EPS $(0.08) Misses $(0.06) Estimate, Sales $2.28M Miss $3.70M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is unchanged from the same period last year. The…
-
1 year ago benzinga.com
Uncovering Potential: Compugen's Earnings Preview
Uncovering Potential: Compugen's Earnings Preview
-
1 year ago benzinga.com
Compugen Q4 2024 GAAP EPS $(0.07) May Not Be Comparable To $0.07 Estimate, Sales $1.47M May Not Be Comparable To $17.43M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.07 by 200 percent. This is a 163.64 percent decrease over earnings of $0.11 per…
-
1 year ago benzinga.com
Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies
The company announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced…
-
1 year ago benzinga.com
Compugen Q3 2024 GAAP EPS $0.01 Misses $0.06 Estimate, Sales $17.132M Miss $17.862M Estimate
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.06 by 83.33 percent. The company reported quarterly sales of $17.132 million…
-
1 year ago benzinga.com
Earnings Scheduled For November 12, 2024
Earnings Scheduled For November 12, 2024